WO1999022731A1 - Method and composition for treatment of sexual dysfunction - Google Patents
Method and composition for treatment of sexual dysfunction Download PDFInfo
- Publication number
- WO1999022731A1 WO1999022731A1 PCT/AU1998/000906 AU9800906W WO9922731A1 WO 1999022731 A1 WO1999022731 A1 WO 1999022731A1 AU 9800906 W AU9800906 W AU 9800906W WO 9922731 A1 WO9922731 A1 WO 9922731A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- milrinone
- alpha
- injection
- atropine
- erection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Definitions
- the present invention relates to the treatment of erectogenic dysfunction in males, and to the treatment of anorgasmia in women.
- Milrinone is a type III PDE inhibitor, which functions as a positive inotrope and vasodilator in its conventional clinical use, but has various adverse reactions. These include ventricular arrhymias, ventricular extopic activity, ventricular tachycardia, and ventricular fibrillation. It is accordingly not desirable administer large doses, particularly when many patients are middle aged and older men who may well be susceptible to cardiovascular or circulatory disorders. Trials by the inventor have indicated that Milrinone is not effective as an erectogenic agent when administered alone at safe doses. Milrinone is a powerful vasoactive substance, and administration of substantial doses by, for example, penile injection carries a risk of deleteriously effecting the circulatory system as a whole. It is one object of the present invention to provide a composition including milrinone which is as or more effective than existing compositions in the treatment of impotence. It is a further object of the present invention to provide an improved method of treatment for impotence.
- Another object of the present invention is to provide a new composition and method of treatment for female anorgasmia.
- the present invention provides in one aspect a composition for use in the treatment of sexual dysfunction, comprising an effective amount of milrinone, a pharmaceutically acceptable carrier or diluent, and one or more agents selected from the group comprising an alpha-adrenergic blocker, a phosphodiesterase inhibitor, a PGE prostaglandin type E, an atropinic agent, with the alpha blocker itself being composed of one part alpha 1 and one part alpha 2.
- the present invention comprises a method of treating sexual dysfunction in a mammal, which comprises administering to said mammal a effective amount of a composition comprising in combination Milrinone, and one or more therapeutically active agents selected from the group comprising an alpha-adrenergic blocker composed of one part alpha 1 and one part alpha 2, a phosphodiesterase inhibitor, a PGE type prostaglandin, and an atropinic agent.
- a composition comprising in combination Milrinone, and one or more therapeutically active agents selected from the group comprising an alpha-adrenergic blocker composed of one part alpha 1 and one part alpha 2, a phosphodiesterase inhibitor, a PGE type prostaglandin, and an atropinic agent.
- the composition is administered by intracavemous injection, topical, transdermal, or intraurethrally.
- the present invention comprises the use of milrinone in the manufacture of a medicament for the treatment of sexual dysfunction, said medicament comprising an effective amount of milrinone and a pharmaceutically acceptable carrier or diluent.
- the medicament further comprises one or more further therapeutic agents which either facilitate, potentiate or are erectogenic.
- additional therapeutic agents are selected from the group comprising an alpha-adrenergic blocker composed of one part alpha 1 and one part alpha 2, a phosphodiesterase inhibitor, a PGE prostaglandin type, and an atropinic agent .
- the present invention will be described and exemplified in relation to several particular compositions and comparative trials as set out below. It is emphasised, however, that the precise dosage and treatment regime will be determined by the attending physician, depending upon the particular circumstances of each patient - for example age, response to particular medications, general health and cardiovascular condition. Hence, the precise dosages and elements of the therapeutic compositions will vary in any true clinical situation.
- he erectogenic activity of milrinone alone or in combination with papaverine, chlorpromazine, phentolamine, atropine, yohimbine and prostaglandin E1 was compared to that of combinations of papaverine, chlorpromazine, phentolamine, atropine, yohimbine and prostaglandin E1.
- Phentolamine Atropine versus Phentolamine. Atropine. Milrinone: After the injection of phentolamine 2 mg. and atropine 0.2 mg. into 9 patients, all 9 showed no response (grades 1).
- the mean latency time between injection and erection was 9 minutes and the mean duration of erection was 78 minutes.
- Atropine Milrinone: After the injection of papaverine 1 1.25 mg., phentolamine 2 mg. and atropine 0.2 mg. into 14 patients, 8 (57%) achieved erections with rigidity of grades 4 to 5 and the other 6 (43%) had tumescence without rigidity (grade 3).
- the mean latency time between injection and erection was 8 minutes and the mean duration of erection was 98 minutes.
- milrinone acts on a post-receptor level via the inhibition of phosphodiesterase (the consequent increase in cyclic adenosine monophosphate attenuates the ⁇ 1 (alpha 1) receptor-mediated contraction of the smooth muscle cell, possibly by interfering with the calcium ion-mobilisation).
- alpha blocking properties of yohimbine seem to be at least as effective as phentolamine if not more so, whereas prostaglandin E1 acts via a membrane- receptor.
- Atropine works by potentiating the action of the other active products on pathological erectile tissue by interfering with the mechanisms that trigger the relaxation of smooth muscle, especially the EDRF (Endothelium Releasing Factor).
- milrinone included at a relatively low dose in a composition for the treatment of impotence enhances the effectiveness of the composition in a way which does not correlate with the activity of Milrinone alone or with the activity of the other components of the composition even when theses other components are used in combination.
- a further advantage of the present invention is that it allows prostaglandin
- prostaglandin E1 produces significant side effects (pain at the site of the injection) while other patients have only a weak response to weak response to prostaglandin E1 (due to a low receptor density). It will be understood that analogues to the components described above may exhibit similar clinical activity to those particularly discussed, and that the present invention is not limited to the specific compounds discussed above in combination with Milrinone.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002315221A CA2315221A1 (en) | 1997-10-30 | 1998-10-30 | Method and composition for treatment of sexual dysfunction |
EP98952416A EP1028726A1 (en) | 1997-10-30 | 1998-10-30 | Method and composition for treatment of sexual dysfunction |
AU10116/99A AU1011699A (en) | 1997-10-30 | 1998-10-30 | Method and composition for treatment of sexual dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP0103A AUPP010397A0 (en) | 1997-10-30 | 1997-10-30 | Method and composition for treatment of sexual dysfunction |
AUPP0103 | 1997-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999022731A1 true WO1999022731A1 (en) | 1999-05-14 |
Family
ID=3804383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1998/000906 WO1999022731A1 (en) | 1997-10-30 | 1998-10-30 | Method and composition for treatment of sexual dysfunction |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1028726A1 (en) |
KR (1) | KR19990037550A (en) |
AU (1) | AUPP010397A0 (en) |
CA (1) | CA2315221A1 (en) |
WO (1) | WO1999022731A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1097706A1 (en) * | 1999-11-08 | 2001-05-09 | Pfizer Limited | Phosphodiesterase inhibitors for the treatment of female sexual dysfunction |
WO2001041807A2 (en) * | 1999-12-10 | 2001-06-14 | Vivus, Inc. | Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US7176238B1 (en) | 1999-03-01 | 2007-02-13 | Nitromed Inc. | Nitrostated and nitrosylated prostaglandins, compositions and methods of use |
CN100337629C (en) * | 2004-04-07 | 2007-09-19 | 鲁南制药集团股份有限公司 | Milrinone sodium chloride injection and production thereof |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
CN104739759A (en) * | 2015-04-02 | 2015-07-01 | 海南合瑞制药股份有限公司 | Pharmaceutical composition containing milrinone compound |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005172A1 (en) * | 1993-08-13 | 1995-02-23 | Zonagen, Inc. | Methods for modulating the human sexual response |
DE4338948A1 (en) * | 1993-11-15 | 1995-05-18 | Carlen Judith | Treating erectile dysfunction without causing side-effects |
US5583144A (en) * | 1995-02-24 | 1996-12-10 | Kral; John G. | Methods for treating erectile impotence |
-
1997
- 1997-10-30 AU AUPP0103A patent/AUPP010397A0/en not_active Abandoned
-
1998
- 1998-10-30 EP EP98952416A patent/EP1028726A1/en not_active Withdrawn
- 1998-10-30 WO PCT/AU1998/000906 patent/WO1999022731A1/en not_active Application Discontinuation
- 1998-10-30 KR KR1019980046467A patent/KR19990037550A/en not_active Application Discontinuation
- 1998-10-30 CA CA002315221A patent/CA2315221A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005172A1 (en) * | 1993-08-13 | 1995-02-23 | Zonagen, Inc. | Methods for modulating the human sexual response |
DE4338948A1 (en) * | 1993-11-15 | 1995-05-18 | Carlen Judith | Treating erectile dysfunction without causing side-effects |
US5583144A (en) * | 1995-02-24 | 1996-12-10 | Kral; John G. | Methods for treating erectile impotence |
Non-Patent Citations (5)
Title |
---|
ANALES D'UROLOGIE, Vol. 25, No. 2, (1991), STIEF C.G., "Pathophysiology of Erectile Dysfunction Due to Cavernous Venous Insufficiency", pages 64-66. * |
INT. J. IMPOTENCE RES., Vol. 8, No. 3, September 1996, STIEF et al., "The Effect of the Specific Phosphodiesterase (PDE) - Inhibitors on Human Rabbit Cavernous Tissue In Vitro and In Vivo", page 127, Abstract D20. * |
J. UROLOGY, Vol. 159, No. 4, April 1998, STIEF et al., "The Effect of the Specific Phosphodiesterase (PDE) Inhibitors on Human and Rabbit Cavernous Tissue In Vitro and In Vivo", pages 1390-1393. * |
SPANWASSER et al., "The Effects of Inhibitors of Phosphodiesterase (PDE) on Smooth Muscle Relaxation of Human and Rabbit Isolated Cavernasal Tissue", Abstract D22. * |
THE MERCK INDEX, 12 Edn 1996, MERCK & CO., Mon. No. 6284, 1036, 7417, 2238, 8063, 8064, 7151, 907. * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6462044B2 (en) | 1996-11-01 | 2002-10-08 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6930113B2 (en) | 1996-11-01 | 2005-08-16 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US7176238B1 (en) | 1999-03-01 | 2007-02-13 | Nitromed Inc. | Nitrostated and nitrosylated prostaglandins, compositions and methods of use |
US7772278B2 (en) | 1999-03-01 | 2010-08-10 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and methods of use |
US7449595B2 (en) | 1999-03-01 | 2008-11-11 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and methods of use |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
EP1097706A1 (en) * | 1999-11-08 | 2001-05-09 | Pfizer Limited | Phosphodiesterase inhibitors for the treatment of female sexual dysfunction |
EP1097707A1 (en) * | 1999-11-08 | 2001-05-09 | Pfizer Limited | Treatment of female sexual dysfunction |
US6734186B1 (en) | 1999-11-08 | 2004-05-11 | Pfizer Inc. | Compounds for the treatment of female sexual dysfunction |
WO2001041807A3 (en) * | 1999-12-10 | 2002-02-14 | Vivus Inc | Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
WO2001041807A2 (en) * | 1999-12-10 | 2001-06-14 | Vivus, Inc. | Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9579270B2 (en) | 2000-03-31 | 2017-02-28 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9675539B2 (en) | 2000-03-31 | 2017-06-13 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
CN100337629C (en) * | 2004-04-07 | 2007-09-19 | 鲁南制药集团股份有限公司 | Milrinone sodium chloride injection and production thereof |
CN104739759A (en) * | 2015-04-02 | 2015-07-01 | 海南合瑞制药股份有限公司 | Pharmaceutical composition containing milrinone compound |
Also Published As
Publication number | Publication date |
---|---|
CA2315221A1 (en) | 1999-05-14 |
AUPP010397A0 (en) | 1997-11-20 |
EP1028726A1 (en) | 2000-08-23 |
KR19990037550A (en) | 1999-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nehra et al. | Rationale for combination therapy of intraurethral prostaglandin E1 and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy | |
CA2636638C (en) | A method of treating an acute vascular disorder | |
EP1028726A1 (en) | Method and composition for treatment of sexual dysfunction | |
WO2002076481A1 (en) | Composition and method of use in treating sexual dysfunction using cgmp-specific phosphodiesterase type 5 inhibitors | |
Chao et al. | Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction | |
Ayd Jr | A preliminary report on Marsilid | |
Costa et al. | Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo | |
Zentgraf et al. | Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine | |
Nicholson et al. | Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer | |
Marshall et al. | Improved hemodynamic response after long-term intracavernous injection for impotence | |
Fouad et al. | Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril). | |
Lee et al. | Dexfenfluramine as a mitogen signals through the formation of superoxide anion | |
EP0618798B1 (en) | Pyridylguanidine compounds for treatment of erectile dysfunction | |
US6803060B2 (en) | Composition to boost libido | |
Andersson et al. | Oral α adrenoceptor blockade as a treatment of erectile dysfunction | |
AU1011699A (en) | Method and composition for treatment of sexual dysfunction | |
EP0305181A2 (en) | Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin | |
US4687771A (en) | Method for treatment of male impotence | |
Nakada et al. | Primary aldosteronism treated by trilostane (3, β-hydroxysteroid dehydrogenase inhibitor) | |
Shmueli et al. | Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents | |
Awadzi et al. | The chemotherapy of onchocerciasis IX: The effect of prednisone plus cyproheptadine on the Mazzotti reaction | |
Tarhan et al. | Effect of intracavernosal sodium nitroprusside in impotence | |
KR19990069591A (en) | Sexual Dysfunction Therapeutics and Treatment Methods | |
Riley | Alpha adrenoceptors and human sexual function | |
RU2111749C1 (en) | Administration of atipamezole for treating sexual male impotence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10116/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 504802 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998952416 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2315221 Country of ref document: CA Kind code of ref document: A Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1998952416 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09555458 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 10116/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998952416 Country of ref document: EP |